364 related articles for article (PubMed ID: 30715379)
1. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
Ross TM
J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
[TBL] [Abstract][Full Text] [Related]
2. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
Krammer F; Palese P
J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
[TBL] [Abstract][Full Text] [Related]
3. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
[TBL] [Abstract][Full Text] [Related]
4. Making Universal Influenza Vaccines: Lessons From the 1918 Pandemic.
Morens DM; Taubenberger JK
J Infect Dis; 2019 Apr; 219(Suppl_1):S5-S13. PubMed ID: 30715352
[TBL] [Abstract][Full Text] [Related]
5. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies.
Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790
[TBL] [Abstract][Full Text] [Related]
6. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
[TBL] [Abstract][Full Text] [Related]
8. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
Zost SJ; Wu NC; Hensley SE; Wilson IA
J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
[TBL] [Abstract][Full Text] [Related]
9. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
Settembre EC; Dormitzer PR; Rappuoli R
J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
[TBL] [Abstract][Full Text] [Related]
10. Universal influenza vaccines, science fiction or soon reality?
de Vries RD; Altenburg AF; Rimmelzwaan GF
Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
Eichelberger MC; Monto AS
J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
13. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
Rudraraju R; Mordant F; Subbarao K
J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
[No Abstract] [Full Text] [Related]
14. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
15. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
16. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
17. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
18. Novel universal influenza virus vaccine approaches.
Krammer F
Curr Opin Virol; 2016 Apr; 17():95-103. PubMed ID: 26927813
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.
Allen JD; Ross TM
Front Immunol; 2021; 12():707339. PubMed ID: 34475872
[TBL] [Abstract][Full Text] [Related]
20. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
Allen JD; Ross TM
J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
